Today: 8 June 2026
Browse Category

NYSE:ABBV 30 July 2025 - 30 November 2025

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie shares closed November at about $227, up 32% year to date but down 3% for the week amid Medicare pricing pressures. The stock’s trailing P/E remains above 170 due to one-off charges, while forward P/E is in the mid-teens. Wall Street Zen downgraded AbbVie from “Strong Buy” to “Buy” on November 30. The average analyst price target sits in the mid-$240s.
30 November 2025
·
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie shares closed at $227.70 on November 28, near record highs after a 31.7% year-to-date gain. The company secured a major reimbursement win in Canada for Skyrizi in ulcerative colitis. Institutional investors reported changes in AbbVie holdings. Analysts questioned whether the stock remains undervalued after its recent rally.
29 November 2025
···
AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie closed Friday at $227.70, up 0.02% after a flat session. Canada’s drug agency recommended reimbursement for Skyrizi in ulcerative colitis, and AbbVie finalized a pricing deal with the national negotiator. Institutional investors adjusted positions, with some funds increasing and others reducing stakes. The stock’s year-to-date gain stands near 30–33%.
28 November 2025
·
AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie (ABBV) Stock Today, November 26, 2025: Share Price Dip Amid FDA Win, Medicare Drug Price Cuts and Bullish Options Signals

AbbVie shares fell 1.9% to $227.41 in early U.S. trading Wednesday, pulling back from recent highs after a strong run. The drop follows new Medicare drug price cuts targeting two AbbVie drugs and comes days after FDA approval of EPKINLY combo therapy for follicular lymphoma. Year to date, the stock is up about 30%.
26 November 2025
··
AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie shares closed at $231.80 on Tuesday, up 1.0%, after U.S. Medicare confirmed plans to negotiate prices on 15 drugs, including AbbVie’s Linzess. The stock saw higher-than-average volume and remains about 5% below its 52-week high. Analysts gave mixed views, with a “Moderate Buy” consensus and a $241.85 average price target. AbbVie also launched a new biotech award program in Quebec.
25 November 2025
·
AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

AbbVie Stock Today (ABBV): Near Record Highs on New Cancer Approval, Raised Guidance and Dividend Hike – November 23, 2025

AbbVie closed at $236.28 on November 21, 2025, near its 52-week high and up about 31% year to date. Q3 revenue rose 9.1% to $15.8 billion, led by immunology and neuroscience, while GAAP EPS dropped sharply due to a $2.7 billion R&D charge. The FDA granted full approval for EPKINLY in follicular lymphoma on November 18. AbbVie raised its 2025 revenue and EPS guidance and approved a 5.5% dividend hike for 2026.
23 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones closed at a record 47,927.96 on Nov. 11, 2025, up 1.18%, while the Nasdaq fell 0.25% as Nvidia dropped nearly 3% after SoftBank revealed a $5.8 billion stake sale. The S&P 500 edged higher. In Europe, the FTSE 100 hit a record near 9,900, boosted by Vodafone’s first dividend increase in eight years and rising bets on Bank of England rate cuts.
11 November 2025
········
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie reported Q3 2025 revenue of $15.78 billion, up 9.1% year-over-year, and raised its full-year EPS outlook after new drugs offset Humira’s decline. Shares traded near $228 in late October, up 28% year-to-date, and the board approved a 5.5% dividend increase for 2026. Skyrizi and Rinvoq sales surged, while the FDA expanded Rinvoq’s indications. AbbVie also announced over $10 billion in acquisitions and new manufacturing investments.
31 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

AbbVie shares trade near $229, up 28% year-to-date and outperforming the S&P 500 healthcare index. The stock hit a record high in late September after a patent settlement extended U.S. exclusivity for Rinvoq until 2037. AbbVie announced a $2.7 billion R&D write-off in October, cutting profit guidance. FDA expanded Rinvoq’s use Oct. 13; a recent trial showed Rinvoq outperformed Humira in rheumatoid arthritis.
23 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 20.10.2025

Fed Chair Jerome Powell signaled the central bank may soon pause its balance-sheet runoff, hinting at an end to quantitative tightening. The move could ease monetary conditions and support stocks, though risks remain if earnings weaken. AbbVie and Abbott Laboratories continue to deliver steady dividend growth, appealing to long-term income investors. Walmart’s new OpenAI partnership and AI-driven features have lifted its shares despite sector headwinds.
20 October 2025
···
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

Billion-Dollar Pharma Deals, Biotech Breakthroughs & Global Health Alerts – Biotech & Health News Roundup (Aug 25–26, 2025)

AbbVie agreed to acquire Gilgamesh Pharmaceuticals’ experimental psychedelic depression drug for up to $1.2 billion, planning to advance it to Phase 3 trials. Japan’s Terumo will buy UK-based OrganOx for $1.5 billion, gaining organ preservation technology. LB Pharma filed for a $100 million IPO, the first biotech IPO in six months. Arnatar Therapeutics raised $52 million to develop RNA therapy for Alagille syndrome.
26 August 2025
··
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

From Foldable Phones to Moon Missions: The Biggest Tech News Roundup (July 29–30, 2025)

Samsung unveiled the Galaxy Z Fold7 at $1,999 and the Flip7 FE at $899, with the Fold7 26% thinner and 10% lighter than last year’s model. Opera filed an antitrust complaint in Brazil against Microsoft over Edge’s default status. Sony sued Tencent, alleging Light of Motiram copied Horizon Zero Dawn. Figma raised its IPO price range, targeting an $18.8 billion valuation.
30 July 2025
·············
1 … 3 4 5

Stock Market Today

  • Cotton Futures Bounce Back in Early Monday Trading
    June 8, 2026, 11:32 AM EDT. Cotton futures recovered Monday morning, rising 20 to 56 points after steep declines Friday, including a 240-point drop in July contracts. The US dollar index gained 0.643 points to 100.025, while falling crude oil prices pressured markets. Weekly CFTC data showed speculators cut 1,798 cotton contracts, leaving a net long position at 52,402. USDA export sales reached 11.33 million running bales (RB), slightly down 1% from last year but on pace with projections. Certified cotton stocks at ICE fell to 250,429 bales, with prices mixed: July cotton up 57 points, December up 41, and March futures up 27 points after Friday's losses. Market watchers see these shifts amid export totals matching expectations and ongoing commodity volatility.

Latest articles

Dow Jones gains with chip stocks ahead of inflation data

Dow Jones gains with chip stocks ahead of inflation data

8 June 2026
Chip stocks surged, powering the Nasdaq up 1.72% and the S&P 500 1.09% higher, while the Dow rose 0.48% to 51,110 as investors bought back Friday’s losses after a strong jobs report fueled Fed-rate worries; May CPI inflation data Wednesday and oil prices remain key risks for market direction.
Growth ETFs Draw Attention Again as Investors Eye Big Tech Weighting

Growth ETFs Draw Attention Again as Investors Eye Big Tech Weighting

8 June 2026
Invesco QQQ Trust surged 2.2% and Vanguard growth ETFs gained over 1% as tech stocks rebounded, spotlighting growth ETFs’ outperformance—VUG returned 15.42% annually over five years, beating VOO—amid record $7.43 billion U.S. equity fund inflows driven by AI-led rallies, but concentrated tech bets mean higher volatility if sentiment shifts, especially with inflation and Fed risks looming.
Alphabet’s $80 billion AI stock sale puts Google’s rally to the test

Alphabet AI Search Drives Wall Street Target Hikes, Cloud Margins Still Draw Scrutiny

8 June 2026
Alphabet has ordered over 3 million TPUs from Intel for 2028 as it ramps up AI infrastructure, prompting Piper Sandler to raise its price target to $445 on rapid AI-assisted search growth, while UBS warns faster Google Cloud TPU revenue could pressure margins; Alphabet shares recently traded at $362.21, down $6.32, after boosting its equity offering to $84.75 billion to finance the AI buildout.
$95 Billion Dividend ETF May Not Be As Safe As It Looks

$95 Billion Dividend ETF May Not Be As Safe As It Looks

8 June 2026
SCHD’s top 10 holdings now make up about 43.5% of assets, raising concentration risk just as investors pile in for safety after a tech-led selloff; with $95.17 billion in assets, a 3.24% yield, and a 0.06% expense ratio, SCHD traded up 0.4% to $32.44 Monday, but its performance and risk profile now hinge more than ever on a handful of big stocks.
Wall Street’s Chip Rebound Lifts Nasdaq — Inflation Test Comes Next

Wall Street’s Chip Rebound Lifts Nasdaq — Inflation Test Comes Next

8 June 2026
Intel soared 8.5% to lead a 4.6% surge in chip stocks after reports Alphabet tapped it to make 3 million in-house chips and Nvidia was evaluating its technology, powering a 1.43% Nasdaq jump as investors returned to AI trades ahead of Wednesday’s key inflation data; Citigroup raised its S&P 500 target to 8,100, but Goldman Sachs warned the Fed may keep rates unchanged through 2026.
Go toTop